IDH2: A Potential Drug Target and Biomarker for Mitochondrial Encephalopathies

Target Name: IDH2

NCBI ID: G3418

IDH2

IDH2: A Potential Drug Target and Biomarker for Mitochondrial Encephalopathies

Idocitrate dehydrogenase (IDH2), a key enzyme in the tricarboxylic acid (TCA) cycle, has been implicated in various neurological and psychiatric disorders. The IDH2 gene has four splice variants, isoform 1 (NDU1), isoform 2 (NDU2), isoform 3 (NDU3), and isoform 4 (NDU4). IDH2 is a mitochondrial enzyme that catalyzes the conversion of acetyl-CoA to malate-CoA via a critical step in the TCA cycle, which is critical for the production of ATP and the synthesis of aromatic amino acids. The IDH2 gene has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

IDH2 is a potential drug target due to its involvement in the production of ATP, which is crucial for maintaining cellular function and homeostasis. The IDH2 enzyme has been shown to be involved in the production of ATP in various cell types, including neurons and glial cells. Additionally, IDH2 has been shown to play a role in the regulation of cellular metabolism and has been implicated in the pathogenesis of various neurological and psychiatric disorders.

IDH2 is also a potential biomarker for the diagnosis and monitoring of mitochondrial Encephalopathies (MEs), which are a group of neurodegenerative disorders characterized by progressive neuroinflammation and damage to the mitochondria. MEs are known to be associated with various neurological and psychiatric symptoms, including progressive muscle weakness, paralysis, and cognitive impairments, and can be caused by a variety of underlying genetic and environmental factors.

The IDH2 gene has been shown to be involved in the production of IDH, a protein that has been implicated in the pathogenesis of MEs. IDH is a key component of the mitochondrial enzyme complex, which is responsible for the production of ATP and is crucial for the survival of the cell. Additionally, IDH has been shown to play a role in the regulation of cellular metabolism and has been implicated in the pathogenesis of various neurological and psychiatric disorders.

IDH2 has also been shown to be involved in the production of succinyl-CoA, a key intermediate step in the TCA cycle and has been implicated in the production of various compounds, including neurotransmitters, such as dopamine and serotonin. The production of succinyl-CoA by IDH2 is critical for the production of these neurotransmitters, which play important roles in the regulation of mood, appetite, and other physiological processes.

In conclusion, IDH2 is a potential drug target and biomarker for MEs. The production of ATP by IDH2 and its involvement in the production of IDH, succinyl-CoA, and other compounds implicate it in the regulation of cellular metabolism and the production of neurotransmitters, which are critical for the survival and proper functioning of the cell. Further research is needed to fully understand the role of IDH2 in the pathogenesis of MEs and to explore its potential as a drug target and biomarker.

Protein Name: Isocitrate Dehydrogenase (NADP(+)) 2

Functions: Plays a role in intermediary metabolism and energy production (PubMed:22416140, PubMed:19228619). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:22416140, PubMed:19228619)

The "IDH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IDH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets